A comprehensive view of men's health issues. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca, Merck's Lynparza wins EU nod to treat metastatic castration-resistant prostate cancer; 473,000 cases of prostate cancer diagnosed annually in Europe, with 10% to 20% of patients developing CRPC within five years

AstraZeneca and MSD’s Lynparza tablets combined with abiraterone and prednisone or prednisolone now approved in the EU for treatment of metastatic castration-resistant prostate cancer

AstraZeneca reports FDA has extended PDUFA date by three months; extension to provide time for full review of sNDA for Lynparza olaparib combination with abiraterone, prednisone or prednisolone to treat metastatic castration-resistant prostate cancer

Novartis wins EU approval for Pluvicto lutetium Lu 177 vipivotide tetraxetan radiopharmaceutical drug to treat prostate cancer; drug contains radioactive agent that destroys cancer cells, antibody that binds to prostate-specific membrane antigen

Gillette announces support for Movember campaign, consolidating the mustache as a symbol of men's health in Brazil to boost awareness of diseases such as prostate cancer; campaign features Liverpool goalkeeper Alisson Becker growing a mustache in support

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count